Bausch Health Companies Inc

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products. The Bausch + Lomb/International segment consists of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Salix segment consists of sales in the U.S. of GI products. The Ortho Dermatologics segment consists of sales in the U.S. of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices. The Diversified Products segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, in the U.S. of generic products, in the U.S. of dentistry products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.

LAVAL, QC , Sept. 14, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) (the "Company") announced today the results to date of its previously announced offers (the "Exchange Offers") to exchange the existing senior notes set forth in the table below (the "Existing Senior Notes") for up to an aggregate principal amount of $4.0 billion (subject to increase or decrease by the Offerors (as defined below), the "Maximum New Secured Notes Amount") of New Secured Notes (as defined below) and the related solicitations of consents (the "Consent Solicitations" and, together with the Exchange Offers, the "Offers") to amend certain provisions of the indentures (the "Proposed Amendments") with respect to the respective applicable series of Existing Senior Notes.

Bausch Health Announces Early Exchange Offer Results for Exchange Offers and Consent Solicitations

Regeneron Pharmaceuticals

Snap

Let's look at what is behind the surprise rise in these three names—and whether they can continue to pace this month's market rally.

Why These 3 Stocks Are Off to Hot September Starts

LAVAL, QC , Sept. 9, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("the Company"), and its gastroenterology business Salix Pharmaceuticals, today responded to the U.S. Food and Drug Administration's (FDA) tentative approval of the Norwich Pharmaceuticals rifaximin 200 mg product.

Bausch Health Responds to Norwich Pharmaceuticals Tentative FDA Approval for a 200 mg Rifaximin

LAVAL, Quebec , Sept. 8, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) (the "Company") clarified today certain provisions related to its previously announced offers (the "Exchange Offers") to exchange the existing senior notes (the "Existing Senior Notes") for new secured notes (the "New Secured Notes") and related solicitation of consent (the "Consent Solicitation") pursuant to the terms described in an Exchange Offer Memorandum and Consent Solicitation Statement, dated Aug. 30, 2022 (the "Exchange Offer Memorandum").

Bausch Health Clarifies Release Provisions Related to its Exchange Offers and Consent Solicitations

Bausch (BHC) reported earnings 30 days ago. What's next for the stock?

Why Is Bausch (BHC) Up 23% Since Last Earnings Report?

Investors liked that the company was able to restructure some long-term debt.

Why Shares of Bausch Health Rose as Much as 30.3% This Week

In today's rather volatile session, investors looking for big movers do have their fair share to consider. Among the biggest gainers in today's market is Bausch Health (NYSE: BHC ).

Why Is Bausch Health (BHC) Up 17% Today?

LAVAL, Quebec , Aug. 30, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ( "Company") announced today that it has commenced offers (the "Exchange Offers") to exchange the existing senior notes set forth in the table below (the "Existing Senior Notes") for up to an aggregate principal amount of $4.0 billion (subject to increase or decrease by the Offerors, the "Maximum New Secured Notes Amount") of new secured notes, comprised of (i) up to $2.5 billion in aggregate principal amount (the "Maximum First Lien Notes Amount") of new 11.00% First Lien Secured Notes due 2028 (the "New First Lien Notes") and up to $500.0 million in aggregate principal amount (the "Maximum Second Lien Notes Amount") of new 14.00% Second Lien Secured Notes due 2030 (the "New Second Lien Notes" and, together with the New First Lien Notes, the "New BHC Secured Notes"), in each case, to be issued by the Company, and (ii) $1.0 billion in aggregate principal amount (the "Holdco Notes Amount") of new 9.00% Senior Secured Notes due 2028 (the "Intermediate Holdco Secured Notes" and, together with the New BHC Secured Notes, the "New Secured Notes") to be issued by 1375209 B.C. Ltd. (the "Holdco Issuer" and, together with the Company, the "Offerors"), an existing wholly-owned unrestricted subsidiary of the Company that holds 38.6% of the outstanding issued and common shares of Bausch + Lomb Corporation, in each case, pursuant to the terms described in an Exchange Offer Memorandum and Consent Solicitation Statement, dated August 30, 2022 (the "Exchange Offer Memorandum").

Bausch Health Announces Exchange Offers and Consent Solicitations for Certain Existing Senior Notes with Support from Approximately 23% of Outstanding Existing Senior Notes

LAVAL, QC , Aug. 22, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") has transferred common shares in an amount equal to approximately 38.6% of the issued and outstanding shares of Bausch + Lomb Corporation ("Bausch + Lomb") to an existing wholly-owned unrestricted subsidiary of the Company (the "Internal Transfer"). Common shares in an amount equal to approximately 50.1% of Bausch + Lomb continue to be held by a wholly-owned restricted subsidiary of the Company, and Bausch + Lomb itself remains a restricted subsidiary of the Company.

Bausch Health Continuing Process Toward Separating Bausch + Lomb

Bausch (BHC) will appeal to the U.S. Court of Appeals for the Federal Circuit regarding the patent decision for one of its key drugs Xifaxan.

Bausch (BHC) to Appeal Regarding Xifaxan Patent Decision

AppLovin Corp

Digital Turbine

Farfetch

Intellia Therapeutics

Warner Bros Discovery Inc

Generally, Wall Street stock price predictions are hardly the best source of investing ideas that have the most upside. Investors should interpret stocks that analysts claim have the most upside carefully.

7 Stock Price Predictions That Are Actually Worth Listening To

LAVAL, Quebec , Aug. 10, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC), and its gastroenterology business Salix Pharmaceuticals, today announced that, consistent with the company's July 28, 2022, press release, the U.S. District Court of Delaware has issued a decision in the matter of Salix Pharmaceuticals, Ltd. et al v. Norwich Pharmaceuticals, Inc. finding certain XIFAXAN® (rifaximin) 550 mg HE patents valid and infringed and certain XIFAXAN composition and IBS-D patents invalid.

Bausch Health to Appeal XIFAXAN® Patent Decision to U.S. Court of Appeals for the Federal Circuit

Bausch (BHC) Q2 earnings and sales miss in the second quarter. The company cuts its annual guidance due to the uncertainties in the overall operating environment.

Bausch (BHC) Q2 Earnings & Sales Miss, View Cut, Stock Down

CMS Issues New Specific ICD-10 Code K76.82 for HE LAVAL, QC , Aug. 10, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and its gastroenterology business, Salix Pharmaceuticals, ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal (GI) and liver diseases and disorders, today announced its support of the publication of a new specific ICD-10 code from the Centers for Medicare & Medicaid Services (CMS) for hepatic encephalopathy (HE) based on the growing incidence of chronic liver disease in the United States.   Approximately 4.5 million adults in the U.S. have chronic liver disease1.

Salix Supports CMS Announcement of First ICD-10 Code for Hepatic Encephalopathy (HE)

Investors are increasingly realizing the scope of the turnaround project CEO Thomas Appio has on his plate.

Why Bausch Health Stock Tumbled More Than 11% on Tuesday

Bausch Health Companies Inc. (NYSE:BHC ) Q2 2022 Earnings Conference Call August 9, 2022 8:00 AM ET Company Participants Christina Cheng - Senior Vice President, Investor Relations Thomas Appio - Chief Executive Officer Tom Vadaketh - Chief Financial Officer Conference Call Participants Ken Cacciatore - Cowen & Company Annabel Samimy - Stifel Gary Nachman - BMO Greg Fraser - Truist Securities Umer Raffat - Evercore Sahil Dhingra - RBC Operator Good morning and welcome to the Bausch Health Second Quarter 2022 Earnings Conference Call. [Operator Instructions] Please note this event is being recorded.

Bausch Health Companies Inc. (BHC) CEO Thomas Appio on Q2 2022 Results - Earnings Call Transcript

Bausch (BHC) delivered earnings and revenue surprises of -38.20% and 3.84%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Bausch Health (BHC) Q2 Earnings and Revenues Miss Estimates

Bausch Health cut its revenue estimate for the year to a range between $8.05 billion and $8.22 billion, from a $8.25 billion to $8.40 billion earlier range.

Bausch Health Stock Sinks on Earnings Miss and Lowered Guidance

Shares of Bausch Health Cos. Inc. BHC, +4.47% tumbled 11.8% in premarket trading on Tuesday after the company missed revenue expectations for the quarter, reported an unexpected loss, and lowered its revenue guidance for 2022.

Bausch's stock slides 11.8% after announcing Q2 results

Revenues of $1.967 billion Company to appeal anticipated court decision and vigorously defend XIFAXAN intellectual property Balance sheet continues to improve with early retirement of $481 million of long-term debt through open market repurchases Committed to strategic alternatives and will continue to evaluate the distribution of Bausch + Lomb shares as the Company works through patent litigation Updates guidance LAVAL, QC , Aug. 9, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its second-quarter 2022 financial results. "The second quarter was a transitional quarter for Bausch Health as we intensified our focus on the Bausch Pharma and Solta businesses," Thomas J.

BAUSCH HEALTH ANNOUNCES SECOND-QUARTER 2022 RESULTS

Bausch + Lomb Corp

Shares of Bausch + Lomb Corp. BLCO, +4.15% were up 3.1% in premarket trading on Thursday after the eyecare company outperformed earnings and revenue expectations in the second quarter of 2022. Bausch had earnings of $5 million, or 1 cent per share, in the second quarter of the year, down from $44 million, or 13 cents per share, in the same quarter a year ago.

Bausch + Lomb beats earnings and revenue expectations; stock is up 3%

An update on the IPO of Solta Medical and regular top-line and bottom-line numbers will grab investors' attention when Bausch Health (BHC) reports Q2 results.

What's in the Cards for Bausch Health (BHC) Q2 Earnings?

Recent court ruling has severely damaged the value of BHC. Insolvency for BHC is unlikely, primarily because they can unload their stake in BLCO and IPO Solta Medical.

Bausch Health: How To Price The Calamities

Wall Street is still digesting the legal drama impacting embattled pharmaceutical firm Bausch Health (NYSE: BHC ). The company has promised to pursue all available options regarding an unfavorable decision impacting its subsidiary Salix Pharmaceuticals' key therapeutic, Xifaxan.

BHC Stock Continues to Fall as Bausch Health Responds to Court Decision

Bausch Health Companies ( BHC , Financial) received a devastating body blow on Thursday when a U.S. federal court judge invalidated some key patents on its largest product Xifaxan for the treatment of irritable bowel syndrome. The judgement was oral, and full details are not available yet, but Bausch's stock plummeted more than 50% following the news before trading was halted.

News for Bausch Health Companies Inc Stock (BHC)